News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rexahn Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board in Major Depressive Disorder


7/6/2010 10:22:27 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the formation of a scientific advisory board (SAB) in major depressive disorder (MDD). The SAB will actively collaborate with Rexahn on the clinical development of Serdaxin® for the treatment of MDD.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES